Apexigen, Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the initiation of patient enrollment in a Phase 2 clinical trial in collaboration with the University of California San Francisco (UCSF).
http://markets.businessinsider.com/news/stocks/Apexigen-Announces-New-Collaboration-with-UCSF-1005559577
Apexigen Announces New Collaboration with UCSF